Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record.

Remission Rates in Patients With Anxiety Disorders Treated With Paroxetine

Ballenger, James C. · 2004 · The Journal of Clinical Psychiatry

Abstract

BACKGROUND: Approximately 50% to 60% of patients with depression and/or anxiety respond to treatment, but only a minority achieve remission. The continued presence of subsyndromal symptoms in treated depressed (and probably anxious) patients leads to higher relapse rates and increased utilization of health care resources. It is proposed that remission is the appropriate target in the treatment of both depression and the anxiety disorders. AIMS: Rigorous criteria for remission have been proposed for the anxiety disorders and are currently being applied in clinical studies. Using these criteria, data from the paroxetine clinical study database were retrospectively analyzed to determine remission rates following paroxetine treatment across a range of anxiety disorders in the largest analysis of remission data in the anxiety disorders to date. METHOD: These analyses included data from 16 short-term and 6 long-term, randomized, placebo-controlled studies in panic disorder, social anxiety disorder, obsessive-compulsive disorder, posttraumatic stress disorder (short term only), and generalized anxiety disorder (DSM-III-R or DSM-IV). Separate analyses were performed for each disorder, with short- and long-term data analyzed separately. RESULTS: In general, across the range of anxiety disorders studied, in both short- and long-term studies, remission rates were higher for paroxetine compared with placebo, using disorder-specific, global, and functional remission criteria both individually and combined. Remission occurred in a moderate proportion of paroxetine-treated patients after only 8 to 12 weeks of treatment, and longer-term therapy led to even higher remission rates. CONCLUSION: Paroxetine has demonstrated efficacy in treating patients to remission across the range of anxiety disorders studied. Our findings strongly suggest that continuing treatment with paroxetine (and probably other SSRI antidepressants) for 2 to 12 months increases the proportion of patients achieving clinical remission.

Overview

Integrity signals

Registry

Crossref · 10.4088/jcp.v65n1216

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cited by

See all 83

Metadata

Authors
Ballenger, J. C.
Affiliations
Medical University of South Carolina (US)
Corresponding author
Ballenger, James C.
Venue
The Journal of Clinical Psychiatry
Published
2004-12-15
Volume
65
Issue
12
Pages
1696-1707
ISSN
0160-6689 (ISSN-L)
OpenAlex
W2053214446
Cited by
82
References
0
Citations by year
2025: 4 · 2024: 4 · 2022: 3 · 2021: 3 · 2020: 3 · 2019: 2 · 2017: 1 · 2016: 2 · 2015: 3 · 2014: 2 · 2013: 4 · 2012: 1
FWCI
13.61
Type
journal article
Language
en
Open access
closed
Locations
  • The Journal of Clinical Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
Keywords
paroxetine, remission rate, anxiety disorders, selective serotonin reuptake inhibitors, panic disorder, social anxiety disorder, obsessive-compulsive disorder, post-traumatic stress disorder, generalized anxiety disorder, functional remission, long-term treatment, relapse
MeSH terms
Adolescent, Adult, Aged, Anxiety Disorders, Female, Humans, Longitudinal Studies, Male, Middle Aged, Obsessive-Compulsive Disorder, Phobic Disorders, Placebos, Psychiatric Status Rating Scales, Retrospective Studies, Stress Disorders, Post-Traumatic, Randomized Controlled Trials as Topic, Panic Disorder, Treatment Outcome, Selective Serotonin Reuptake Inhibitors, Paroxetine

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Remission Rates in Patients With Anxiety Disorders Treated With Paroxetine. https://app.cochat.ai/papers/10.4088/jcp.v65n1216
The paper
Ballenger, J. C. (2004). Remission Rates in Patients With Anxiety Disorders Treated With Paroxetine. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.v65n1216

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.